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Relapsing varicella may occur in children with HIV infection and more rarely in younger adults. Our aim
was to report unusual clinical, histologic, and virologic aspects of 4 elderly patients with malignant
hemopathies who had an unusual form of recurrent varicella develop. Conventional microscopy, immu-
nohistochemistry, and in situ hybridization were applied to smears and skin biopsy specimens. The patients
presented a few dozen, scattered, large, papulovesicular lesions with central crusting. No zoster-associated
pain or dermatomal distribution of the lesions was noted. Conventional microscopy revealed vascular
changes and epidermal alterations typical for -herpes virus infection. The varicella zoster virus major viral
envelope glycoproteins gE and gB, and the immediate-early varicella zoster virus IE63 protein and the
corresponding genome sequence for gE were detected on Tzanck smears; they were localized in endo-
thelial cells and keratinocytes on skin biopsy specimens. The varicella zoster virus infection in endothelial
cells, the vascular involvement, and the widespread distribution of the lesions suggest that the reported
eruptions are vascular rather than neural in origin. These findings invalidate the diagnosis of herpes zoster
but strongly support the diagnosis of recurrent varicella in an indolent and yet unreported presentation.
Furthermore, these eruptions differ from relapsing varicella in children and young adults by the age of the
patients, the paucity of clinical lesions, the larger diameter of the lesions and their peculiar clinical aspect,
the significantly longer time interval between primary varicella and the recurrence, the prolonged healing
time of the lesions, their mild disease course, and the fact that all the lesions are in the same stage of
development. (J Am Acad Dermatol 2003;48:442-7.)
T he first contact with varicella zoster virus(VZV) leads to an infection of the upper re-spiratory airways, followed by a primary vire-
mia that remains clinically silent. This primary vire-
mia is halted by the nonspecific immune defense
mechanism of the host. Subsequently, viral replica-
tion occurs in the liver, spleen, and probably other
organs. This viral replication is then followed by a
massive release of viral particles in the bloodstream.
This secondary viremia finally leads to the invasion
of cutaneous tissues and the development of typical
varicella skin lesions.1,2 Subsequently, the virus re-
mains in a latent state in the dorsal root ganglia,
where specific VZV protein expression takes
place.3-5 During varicella, there is a usual serocon-
version with the development of specific anti-VZV
IgM and IgG antibodies. The progressive fading of
the specific IgM antibodies leads to the classic IgG,
IgM status proving past varicella infection.1,2 On
reactivation, the virus usually migrates from the dor-
sal root ganglia along axons to the skin where it
produces a cytolytic infection in the keratinocytes
resulting in shingles.6,7
In the otherwise normal population herpes zoster
and varicella usually occur each as single episodes.
In patients who are immunocompromised relapsing
shingles,8 other atypical VZV-related cutaneous in-
fections,9-12 and recurrent VZV retinitis13 have been
described. Recurrent varicella has also been re-
ported in children infected with HIV and in children
with cancer.9,10,14-18 Although exceptional, relapsing
varicella has been described in young adults with
HIV infection19,20 or neoplasia.21 In such patients,
lesions may affect many organs with devastating
morbidity and even mortality.7,22 Primary varicella
infection and its recurrent type in children and
young adults are clinically indistinguishable,9,10,14-21
but are serologically different as the first is associ-
ated with seroconversion and the latter possesses a
IgG, IgM status of past primary varicella infection.
From the Departments of Dermatopathologya and Fundamental Vi-
rology,d University Medical Center of Lie`ge; and the Departments
of Dermatology,b Hematology,c and Virology,e Erasme University
Medical Center.
Supported by a grant from the Belgian Fonds de la Recherche Sci-
entifique Me´dicale to Drs Nikkels and Pie´rard.
Reprint requests: Arjen F. Nikkels, MD, PhD, Department of Dermato-
pathology, CHU Sart Tilman, B-4000 Lie`ge, Belgium. E-mail:
af.nikkels@chu.ulg.ac.be.




The purpose of this article is to describe the
clinical, histologic, and virologic features of 4 elderly
patients who exhibited an unusual type of recurrent
varicella after chemotherapy for malignant hemop-




The clinical characteristics are reported in Table I.
Serologic status of past VZV and herpes simplex
virus (HSV) infections (IgM, IgG), as determined
by enzyme-linked immunosorbent assay, was
known for all the patients before the occurrence of
the presently reported eruptions.
Laboratory examinations
Microscopy. Smears were collected from pa-
tients 1, 2, and 4 on silanized glass slides. One smear
was stained for 1 minute with a toluidine blue and
basic fuchsin solution (polychrome multiple stain,
Delasco, Council Bluffs, Iowa).20 Other smears were
used for immunohistochemistry.
Skin biopsies were obtained from patients 2, 3,
and 4 from the periphery of the lesions under local
anesthesia with lidocaine 1% and 1/106 adrenalin.
The samples were formalin-fixed (neutralized for-
malin 10%) and paraffin-embedded for routine pro-
cessing. A 5 m—thick section was stained with
hematoxylin and eosin. Other sections were pre-
pared on silanized slides for immunohistochemistry
and in situ hybridization.
Viral culture. In patient 1 viral isolation was
obtained on culture. Subsequent immunofluores-
cence identification on viral culture was performed
using a mouse monoclonal anti-VZV antibody (Ar-
gene Biosoft, Varilhes, France). Anti-HSV antibodies
were included as controls.
Immunohistochemistry. In patients 2, 3, and 4
immunohistochemistry using the labeled streptavi-
din-biotin method was performed on smears and
skin biopsies after a previously described proto-
col.23,24 The mouse monoclonal anti-VZV antibodies
VL8 and VL2 were used to detect the envelope
glycoproteins gE and gB, respectively.23 The rabbit
polyclonal antibody anti-IE63 was also included.4 A
rabbit polyclonal anti-HSV I antibody (Dakopatts,
Glostrup, Denmark) was also used on smears and
biopsies. Primary antibody omission and immuno-
staining on normal skin served as controls.
In situ hybridization. In situ hybridization was
carried out on biopsies from patients 2, 3, and 4 as
described previously.23 The 16.6-kilobase EcoRI-A
restriction endonuclease fragment of VZV DNA, cor-
responding to gE, and an anti-HSV probe (Enzo
Diagnostics, New York, NY) were used to detect




Table II summarizes some clinical aspects of the
skin lesions. They consisted of large (1-4 cm), well-
demarcated, isolated, vesiculopapular lesions with
central crusting or necrosis (Fig 1, a through d). No
dermatomal clustering of the lesions, indicating her-
pes zoster, could be evidenced. Prodromal and con-
comitant pain was not experienced by the patients.
Only patient 1 had mild headache, fever, and ar-
thralgia during the first recurrent episode. Secondary
Table I. Patient characteristics
Patient
No. Age (y)/Sex Hemopathy
Chemotherapeutic
regimen
Time interval between the last
chemotherapy course and the
appearance of lesions
1 40/M Chronic lymphocytic leukemia 1. Chlorambucil and
methylprednisolone
2 mo
2. Dexa-beam 5 days, 2 mo
2 65/M Multiple myeloma IgG  type VPMC (1 course) 4 wks
3 70/M Multiple myeloma IgA  type VPMC (5 courses) 20 days
4 86/F Chronic neutrophilic leukemia Hydroxyurea Unknown
Dexa-beam, Dexamethasone, carbustine, etoposide, cytarabine, and melphalan; VPMC, vincristine, prednisolone, melphalan, and cyclophosph-
amide.




No. of lesions Anatomic sites
Healing
time (days)
1 Episode 1: 40 Trunk, scalp, limbs 13
Episode 2: 10 Head, abdomen, limbs 12
Episode 3: 10 Limbs, R foot 10
2 20 Trunk, R arm 9
3 30 L arm, trunk, face 14
4 20 Entire tegumentum 12
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hypopigmented varioliform scars were noted in pa-
tients 1, 2, and 4. Patients 2, 3, and 4 experienced a
single recurrent episode without any evidence of
herpes zoster lesions. Patient 1 presented 3 relapses
of such atypical varicelliform lesions. On diagnosis
all the patients were treated with intravenous acy-
clovir (Zovirax, Glaxo Wellcome, London, UK) (10
mg/8 h for 8-10 days). As a result of the recurrent
character of the lesions, after the third relapse pa-
tient 1 received a prophylactic antiviral regimen with
oral valacyclovir (Zelitrex, Glaxo Wellcome) (4 
500 mg daily) for 10 months, after which the treat-
Fig 1. a, Scattered large erythematopapular lesions with central crusting on the abdomen
(patient 1). b, Large erythematopapular lesions on a limb (patient 1). c, Large lesion on the arm
(patient 3). d, Three large erythematopapular lesions on the back (patient 2). e, Immunohis-
tochemic detection (red signal) of the gE VZV envelope glycoprotein on a Tzanck smear (Mab
VL8; original magnification 100). f, Vascular changes with swollen endothelial cells (hema-
toxylin-eosin stain; original magnification 100). g and h, Immunostaining (red signal)
demonstrating the gE VZV protein in endothelial cells, illustrating the viral vasculitic alterations
(Mab VL8; original magnification 100).
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ment was interrupted without further recurrence of
the lesions.
Laboratory results
The synoptic Table III summarizes the results of
smears, viral culture, VZV serology, immunohisto-
chemistry, and in situ hybridization for every pa-
tient.
Microscopy. Smears of patients 1, 2, and 4 sup-
ported the cytologic diagnosis of -herpesviridae
infection by the presence of multinucleated syncytial
cells with ground glass—appearing nuclei. Histo-
logic examination of the biopsies from patients 2, 3,
and 4 revealed intraepidermal vesiculation contain-
ing multinucleated giant keratinocytes, and a mixed
lymphoneutrophilic infiltrate. Such alterations were
typical for -herpes virus infection. Furthermore,
significant vascular changes were present including
endothelial cell swelling and red blood cell extrav-
asation (Fig 1, f).
Immunohistochemistry. In patient 1 VZV was
identified in the smear and viral culture using im-
munofluoresence. A positive immunohistochemic
signal for VZV was evidenced on the Tzanck smears
of patients 2 and 4 (Fig 1, e). Anti-HSV I antibodies
gave negative results on the smears. Immunohisto-
chemic testing of the skin biopsies of patients 2, 3,
and 4 revealed the presence of VZV gE, gB, and IE63
proteins in epidermal keratinocytes and dermal den-
dritic cells. These VZV components were also
present in endothelial cells at the site of vasculitic
changes (Fig 1, f and h). VZV immunostaining was
not observed in cutaneous nerves. The primary an-
tibody omission, the anti-HSV I antibody, and im-
munostaining on normal skin yielded negative re-
sults.
In situ hybridization. In situ hybridization us-
ing the anti-VZV EcoRI-A probe yielded positive
results in the skin biopsies of patients 2, 3, and 4. A
strong nuclear signal was disclosed in epidermal
keratinocytes and endothelial cells. A weaker signal
was observed in dermal dendritic cells. Probe omis-
sion and the anti-HSV probe gave consistently neg-
ative results.
DISCUSSION
The papulovesicular presentation and the wide-
spread distribution of the lesions recalls varicella
either of the primary or the recurrent type. However,
the absence of general symptoms, the prolonged
healing time, the age of the patients, the paucity and
the larger diameter of the lesions, the concurrent
chemotherapy for hemopathies, the same stage of
development of all the lesions, and particularly the
past primary varicella serologic (IgG, IgM-) status
clearly distinguish the presently reported eruptions
from typical childhood or adult primary varicella.
The pathomechanism of the presently reported
lesions is puzzling. The clinical appearance VZV
infection varies according to the site and type of
infection in the skin.10,23-25 Hence, the vesicular type
of herpes zoster has been associated with viral pres-
ence in the epidermal and pilosebaceous structures
whereas the follicular (or papular) type reveals only
viral expression in the epithelial cells of the pilose-
baceous units.10,23-25 The wartlike expression of VZV
infection in patients with AIDS is associated with a
chronic, noncytolytic infection.10 However, the re-
ported lesions do not correspond to herpes zoster,
because of the absence of dermatomal distribution
and zoster-associated pain so frequently observed in
the elderly patient.6,7 In contrast, besides epidermal
involvement, histologic examination revealed vascu-
lar alterations with swollen endothelial cells. Immu-
nohistochemistry and in situ hybridization evi-
denced VZV infection of endothelial cells. Although
VZV is occasionally observed in endothelial cells
during herpes zoster,24 the significant vascular
changes suggest a vascular rather than neural origin
of the lesions as has been documented for chicken-


















1 -Herpes VZV IF VZV IgG,IgM NA NA NA
2 -Herpes gE, gB, IE63 NA IgG,IgM KC: KC: KC
IHC Vasculitis: EC: EC:
3 NA NA NA IgG,IgM KC: KC: KC:
Vasculitis: EC: EC:
4 -Herpes gE, gB, IE63 NA IgG,IgM KC: KC: KC:
IHC Vasculitis: EC: EC:
-Herpes, Typical cytologic features of-herpesvirus infection; EC, endothelial cell; IF, immunofluorescence; IHC, immunohistochemistry; ISH, in
situ hybridization; KC, keratinocyte; NA, not available; PMS, polychrome multiple stain.
Nikkels et al 445J AM ACAD DERMATOL
VOLUME 48, NUMBER 3
pox.1,2 In fact, the secondary viremia of chickenpox
infects the cutaneous endothelial cells after which
the virus migrates (possibly by dermal dendritic
cells) toward the epidermal keratinocytes producing
a cytolytic infection.1,2 The VZV endothelial cell in-
fection, the vascular changes, and the widespread
distribution of the lesions constitute indirect clues
for the presence of a viremia. Transient subclinical
VZV viremia has been demonstrated in peripheral
blood mononuclear cells of patients with herpes
zoster, and in patients who are VZV seropositive
(IgM, IgG) with no sign of VZV-related dis-
ease.26-28 In the latter patients, the viremic episodes
remain probably subclinical as the patients are VZV-
seropositive and because of the paucity of viral load
compared with that observed during varicella.27,28
On the other hand, previous vascular injury may
create a predilective site for VZV replication, leading
to varicella on photodamaged sites,29 or on other
diverse skin injuries.30,31 Hence, in our patients, the
chemotherapy could have damaged the endothelial
cells, creating predilective sites for viral attachment
and replication. However, this hypothesis is invali-
dated by the different time interval between the
appearance of the lesions and the last chemothera-
peutic course that varied from 5 days to 2 months
(Table I).
Whether this particular type of recurrent varicella
is specifically associated to malignant hemopathies
or specific chemotherapeutic drug regimens remains
to be determined by further observations.
Literature data9,10,14-21 and the current observa-
tions are summarized in Table IV, highlighting spe-
cific differences between primary varicella in chil-
dren and adults; and recurrent varicella in children,
adults, and elderly patients. Primary varicella in chil-
dren and adults can be distinguished from the re-
current type by the VZV-seronegative status. Fur-
thermore, adult primary varicella differs from
childhood chickenpox by its rarity, the more severe
disease course, and the type of complications, in-
volving preferentially the lung and liver compared
with the neurologic complications in children.1,2
Currently reported cases can furthermore be sepa-
rated from recurrent varicella in children and young
adults by the age of the patients, the paucity of
clinical lesions, the larger diameter of the lesions
and their peculiar clinical aspect, the significantly
longer time interval between primary varicella and
the recurrence, the prolonged healing time of the
lesions, the absence of a cephalocaudal progression
of skin lesion appearance, their mild disease course,
and the fact that all the lesions are in the same stage
of development. This last point is in contrast with
primary varicellla where typically erythematous,
papular, vesicular, pustular, and crusted lesions are
simultaneously observed.
The skin lesions cleared in all patients after intra-
venous acyclovir, using dosages recommended for
patients with immunosuppression. The rationale of
oral valacyclovir maintenance therapy is illustrated
by the first patient in whom 3 successive episodes
occurred. More case studies and evaluating of co-
Table IV. Comparison of clinical features between primary varicella and recurrent varicella
Type
Primary varicella Recurrent varicella
Childhood Adulthood Childhood Adults Elderly patients
Frequency Frequent Rare Rare Rare ? (Underrecognize)
VZV serology IgG, IgM IgG, IgM IgG, IgM IgG, IgM IgG, IgM
Underlying disorders HIV, cancer HIV, cancer hemopathies
No. of lesions  100  100  100  100 10-40
Disease course Mild Severe Mild to severe Severe Mild










Lesion stage All stages All stages All stages All stages Single stage
Lesion diameter  1 cm  1 cm  1 cm Variable 1-4 cm
Cephalocaudal
progression
Yes Yes Yes ND NA
Healing time of lesions 5-8 days ND ND Prolonged 9-14 days
Delay between primary
and recurrent varicella
NA NA 5-17 months months-years  30 y
No. of episodes of
recurrent varicella
NA NA 1: 34% of
patients
1 3 relapses: 1 patient
1 relapse: 3 patients
2: 5%,
3-6:1%-11%
NA, Not applicable; ND, no data.
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hort-based therapeutic management are needed to
better mitigate this type of VZV recurrences.
In summary, the evidence of VZV infection in
endothelial cells, the vascular alterations, and the
widespread distribution of the lesions suggest that
the reported eruptions are vascular rather than neu-
ral in origin. The aforementioned histologic and vi-
rologic findings, the recently published evidence of
infraclinical viremia,27,28 the clinical differences with
primary and relapsing varicella, and the absence of
signs for herpes zoster suggest the diagnosis of atyp-
ical recurrent varicella. The atypical clinical presen-
tation is probably bound to underrecognition. This
study should increase awareness for atypical VZV
manifestations and incite further virologic investiga-
tions in the event of unusual skin signs, especially in
the immunocompromised host.
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